Immunome Inc. (IMNM)
NASDAQ: IMNM
· Real-Time Price · USD
11.59
1.44 (14.13%)
At close: Sep 26, 2025, 3:59 PM
11.68
0.74%
After-hours: Sep 26, 2025, 07:54 PM EDT
14.13% (1D)
| Bid | 10.9 |
| Market Cap | 1.01B |
| Revenue (ttm) | 12.59M |
| Net Income (ttm) | -212.39M |
| EPS (ttm) | -3.05 |
| PE Ratio (ttm) | -3.8 |
| Forward PE | -4.87 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 11.75 |
| Volume | 5,858,560 |
| Avg. Volume (20D) | 1,100,552 |
| Open | 10.06 |
| Previous Close | 10.15 |
| Day's Range | 10.06 - 11.66 |
| 52-Week Range | 5.15 - 15.20 |
| Beta | 1.92 |
| Ex-Dividend Date | n/a |
About IMNM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMNM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMNM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsImmunome Inc. is scheduled to release its earnings on
Nov 12, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+7.19%
Immunome shares are trading higher after Lake Stre...
Unlock content with
Pro Subscription
8 months ago
+1.19%
Immunome shares are trading lower after the company announced a $125 million proposed public offering.
3 days ago · proactiveinvestors.com
Immunome stock a ‘buy' on ‘rich pipeline' of oncology therapeutics: analystsImmunome, Inc (NASDAQ: IMNM) has a “rich pipeline of potential best and/or first-in-class targeted oncology therapeutics,” Goldman Sachs analysts wrote in a note to clients on Monday. They initiated...
3 weeks ago · businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...
